Lipoprotein transport and metabolism markers in patients with myocardial infarction in the Biobank of Yugra blood sample collection

Aim. To evaluate clinical associations and predictive value of lipoprotein transport and metabolism markers determined in a collection of serum samples from patients with myocardial infarction (MI).

Material and methods. Collection of blood samples from 88 patients with the acute MI was created in the Biobank of Yugra laboratory for subsequent biochemical assessment of serum levels of lipoprotein transport and metabolism markers. All patients were included in a clinical prospective study for 48 months with registration of medical events and remote tomographic assessment of coronary artery (CA) involvement upon follow-up completion.

Results. Direct associations were established between proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and low-density lipoprotein cholesterol levels, coronary atherosclerosis, Global Registry of Acute Coronary Events (GRACE) 2.0 risk score, and the risk of recurrent acute coronary syndrome. Lipoprotein (a) levels >50 mg/dl were detected in 28,4% of patients with MI and were associated with prior medical events, coronary and non-coronary artery atherosclerosis, comorbidity, recurrent coronary lesions, and the risk of major cardiac events at the end of follow-up. A relationship was established between a high (5,14) triglyceride-glucose index and comorbidity, recurrent coronary lesions, and the death risk at the end of follow-up.

Conclusion. The Biobank of Yugra laboratory is an effective base for laboratory research. Lipoprotein transport and metabolism markers are associated with clinical factors, comorbidity, vascular atherosclerosis and a negative prognosis in patients with MI.

1. Dolgopolov IS, Rykov MYu. The evolution of personalized medicine: literature review. Research and Practical Medicine Journal (Issled. prakt. med.). 2022;9(3):117-28. (In Russ.) doi:10.17709/2410-1893-2022-9-3-9.

2. Shuvalova YA, Moskalenko SA, Kaminnyi AI. Contribution of polymorphisms of genes of the Interleukin-6 system to the development of atherosclerosis. Journal of Atherosclerosis and Dyslipidemias. 2020;4(41):5-11. (In Russ.) doi:10.34687/2219-8202.JAD.2020.04.0001.

3. Mora S. Lp(a)'s Odyssey: Should We Measure Lp(a) Post-ACS and What Should We Do With the Results? J Am Coll Cardiol. 2020;75(2):145-7. doi:10.1016/j.jacc.2019.11.016.

4. Morozkina AV, Vorobyov AS, Donnikov MYu, et al. Creation of a biosample collection from patients after myocardial infarction in the Khanty-Mansi Autonomous Okrug — Yugra. Cardiovascular Therapy and Prevention. 2023;22(11):3805. (In Russ.) doi:10.15829/1728-8800-2023-3805.

5. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/29/1560-4071-2020-4103.

6. Borisova AL, Pokrovskaya MS, Meshkov AN, et al. ISO 20387 biobanking standard. Analysis of requirements and experience of implementation. Russian Clinical Laboratory Diagnostics. 2020;65(9):587-92. (In Russ.) doi:10.18821/0869-2084-2020-65-9-587-592.

7. Emelyanchik VS, Marilovtseva OV, Khomchenkov RV, et al. Lipoprotein(a) in the diagnosis of cardiovascular risk. The values of lipoprotein (a) and apolipoprotein B in the adult population of Krasnoyarsk. Russian Journal of Cardiology. 2023;28(7):5499. (In Russ.) doi:10.15829/1560-4071-2023-5499.

8. Kalinin RS, Goleva OV, Illarionov RA, et al. Development of a biobank in the structure of scientific and diagnostic and treatment institutions and prospects for interregional integration. Cardiovascular Therapy and Prevention. 2022;21(11):3401. (In Russ.) doi:10.15829/1728-8800-2022-3401.

9. Ugovšek S, Šebeštjen M. Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall. J Clin Med. 2022;11(13):3625. doi:10.3390/jcm11133625.

10. Cariou B, Guerin P, Le May C, et al. Circulating PCSK9 levels in acute coronary syndrome: Results from the PC-SCA-9 prospective study. Diabetes Metab J. 2017;43(6):529-35. doi:10.1016/j.diabet.2017.07.009.

11. Bae KH, Kim SW, Choi YK, et al. Serum Levels of PCSK9 Are Associated with Coronary Angiographic Severity in Patients with Acute Coronary Syndrome. Diabetes Metab J. 2018;42(3):207-14. doi:10.4093/dmj.2017.0081.

12. Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One. 2014;9(9):e106294. doi:10.1371/journal.pone.0106294.

13. Gencer B, Montecucco F, Nanchen D, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J. 2016;37(6):546-53. doi:10.1093/eurheartj/ehv637.

14. Drenina YuA, Nikolaev KYu. PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics. Cardiovascular Therapy and Prevention. 2020; 19(4):2484. (In Russ.) doi:10.15829/1728-8800-2020-2484.

15. Simerzin VV, Fatenkov OV, Gagloeva IV, et al. Residual Risk of Cardiovascular Complications in Case of Adequate Lipid-Lowering Therapy. Science and Innovations in Medicine. 2018;3(2):19-25. (In Russ.) doi:10.35693/2500-1388-2018-0-2-19-25.

16. Roth C, Krychtiuk KA, Gangl C, et al. Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: An observational cohort study. PLoS ONE. 2020;15(1):e0227054. doi:10.1371/journal.pone.0227054.

17. Bittner VA, Szarek M, Aylward PE, et al. ODYSSEY OUTCOMES Committees and Investigators. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133-44. doi:10.1016/j.jacc.2019.10.057.

18. Liang S, Wang C, Zhang J, et al. Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. Cardiovasc Diabetol. 2023;22(1):170. doi:10.1186/s12933-023-01906-4.